Journal
PSYCHIATRY AND CLINICAL NEUROSCIENCES
Volume 72, Issue 3, Pages 160-167Publisher
WILEY
DOI: 10.1111/pcn.12618
Keywords
Alzheimer's disease; cognitive function; DNA methylation; gene expression; myocyte-enhancer factor 2C
Categories
Funding
- Health and Labor Science Research Grant from the Japanese Ministry of Health, Labour, and Welfare
- Japanese Ministry of Education, Culture, Sports, Science, and Technology, JSPS KAKENHI [16K21207, 15K09808]
- Grants-in-Aid for Scientific Research [15K09808] Funding Source: KAKEN
Ask authors/readers for more resources
Aim: Despite continuing research into Alzheimer's disease (AD), its pathological mechanisms and modulating factors remain unknown. Several genes influence AD pathogenesis by affecting inflammatory pathways. Myocyte-enhancer factor 2C (MEF2C) is one such candidate gene for AD. Methods: We examined MEF2C mRNA expression levels and methylation rates of CpG on its promoter region in peripheral leukocytes from Japanese AD patients compared with age-and sex-matched control subjects. Results: In peripheral leukocytes, MEF2C mRNA expression levels in AD subjects were significantly lower than those in control subjects (0.86 +/- 0.25 vs 0.99 +/- 0.27, respectively, P = 0.007) and were correlated with the Alzheimer's Disease Assessment Scale (r = -0.345, P = 0.049) and the Mini Mental State Examination (r = 0.324, P = 0.02). No significant differences were found in methylation rates between AD and control subjects. Conclusion: MEF2C mRNA expression in leukocytes may be a biological marker for cognitive decline in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available